Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline - discovered using the DIAGONAL platform - has the potential to deliver life-changing therapies to patients by tackling the underlying cause of disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/03/24 | $128,000,000 | Series A |
Atlas Venture BVF Partners Checkpoint Capital Frazier Life Sciences Lightspeed Venture Partners RA Capital Management Velosity Capital Viking Global Investors | undisclosed |
| 01/12/26 | $125,000,000 | Series B |
Atlas Venture Balyasny Asset Management Biovision Ventures BVF Partners Checkpoint Capital Deep Track Capital EcoR1 Capital Frazier Life Sciences Janus Henderson Investors Lightspeed Venture Partners Logos Capital RA Capital Management RV Invest Sanofi Ventures Velosity Capital Viking Global Investors Woodline Partners | undisclosed |
